TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05324761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300mg
Description: Each patient complaining of pain associated with spine surgery who is randomly enrolled this arm of the study and start the specific medication of the arm with the recommended dose and duration for a period of one month, patient will be followed regularly regarding compliance to doses and to register any side effect.
Study: NCT06394362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bispectral index monitor
Description: Bispectral Index (BIS), that was introduced in 1992, is a tool that monitors the depth level of hypnosis through data processing of an electroencephalogram using computer algorithm and presented in the form of processed EEG. Utilizing BIS as a monitoring tool has shown effectiveness in reducing recovery time, prevent awareness, and bring down the amount of anesthesia agent however, as of now, it has not been incorporated into the 2020 American Society of Anesthesiologists (ASA) standard procedure on anesthesia monitoring. aims to comparing the deep hypnotic time duration on two group of geriatric patients which undergoes general anesthesia with BIS monitoring compared to standard monitoring.
Study: NCT06435065

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Biodentine
Description: DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mineral Tri-Oxide Aggregate
Description: DIRECT PULP CAPPINGWILL BE DONE USING MTA

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: THERACAL LC
Description: DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRISTRONTIUM ALUMINATE
Description: DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
Study: NCT04672161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine Education
Description: A baseline educational intervention on vaccination and its role in the health maintenance of patients with IBD will be provided to all participants. Those on immunosuppressive therapies and/or those age 65 or older will also be offered the pneumonia vaccine educational intervention. Finally, patients aged 18-26 and those 27-45 who have never been vaccinated for HPV or those with high risk for HPV will additionally receive the HPV educational intervention.
Study: NCT06098859

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: Thoracic epidural analgesia was started preoperatively and rest posoperative 48 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was applied preoperatively using local anesthetic
Study: NCT06068387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical staging
Description: para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
Study: NCT05916404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity high-intensity interval aerobic exercise training
Description: High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (\<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
Study: NCT06228612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum therapy
Description: vacuum therapy :all patients were informed about initial suction sensation and possible appearance of bruising at the application site. Basic vacuum therapy equipment (cangexia, China) was utilized including a manual suction pump, plastic cups of 40 mm diameter with rolled edge, and anti-septic tools.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary stabilization splint (MSS)
Description: maxillary stabilization splint (MSS): was constructed for each patient from hard, heat-cured clear acrylic resin and fitted to the maxillary teeth. On the mounted master casts, the vertical dimension was adjusted to provide 3 mm of vertical space between the closest opposing cusps of the maxillary and mandibular teeth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vacuum therapy VT and maxillary stabilization splint (MSS)
Description: vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
Study: NCT06545487

Intervention type: OTHER
Intervention: BLOOD SAMPLE
Description: BLOOD ANALYTICS IN SEVERAL PARAMETERS

Intervention type: OTHER
Intervention: BLOOD SAMPLE
Description: BLOOD ANALYTICS IN SEVERAL PARAMETERS
Study: NCT05700474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient behavioral health care
Description: Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
Study: NCT04887402

Intervention type: DRUG
Intervention: Clomiphene Citrate
Description: All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation

Intervention type: DRUG
Intervention: Clomiphene Citrate
Description: All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation
Study: NCT05379101

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiogram (TTE)
Description: An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiogram (TTE)
Description: An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute Walk Test
Description: A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute Walk Test
Description: A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute Walk Test
Description: A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute Walk Test
Description: A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
Study: NCT05194254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-ET
Description: coupled fMRI and Eye Tracking tools

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI-ET
Description: coupled fMRI and Eye Tracking tools
Study: NCT05585034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®808
Description: Monoclonal bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda® (pembrolizumab)
Description: Monoclonal antibody
Study: NCT06548763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 1.4mg/㎡, orally administered, d1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg, intravenous drip, d1, q3w
Study: NCT06461910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Combined with Thymosin and SOX
Description: Anti-PD-1 Combined with Thymosin and SOX in Neoadjuvant Treatment of cStage IIII Gastric or Esophagogastric Junctional Adenocarcinoma
Study: NCT05798845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+LDRT
Description: primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/4Fx, d1-4, d22-25 (2 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: toripalimab 240mg ivgtt d5, d26 (2 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: toripalimab 240mg ivgtt d1, d22 (2 cycles)
Study: NCT06549400

Intervention type: DRUG
Group type: OTHER
Intervention: Mexiletine granules for prolonged-release oral suspension
Description: Mexiletine PR
Study: NCT04180904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 1
Description: Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
Study: NCT05361629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional steroid administration
Description: Treatment by administering steroids into the lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative cavity steroid administration
Description: Treatment by administering steroids into the surgical cavity
Study: NCT04180904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 2
Description: This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
Study: NCT05280093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure ISOLATOR Synergy Surgical Ablation System
Description: Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
Study: NCT04343924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scuba diving activities
Description: The subjects of this group daily dive, 5 days per week, for a total of 10 dives at a maximum depth of 6 meters for a maximum duration of 20 minutes in a swimming pool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality activities
Description: The subjects of this group will follow virtual reality sessions recreating the environment in which the submarine diver of the GP+ group operates
Study: NCT04674566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-101
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-101
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-101
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-101
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered intravenously (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered intravenously (IV) single dose
Study: NCT06549140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality exercise program
Description: Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide an entire exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercise program
Description: Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
Study: NCT05340985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D3
Description: calcifediol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Cholecalciferol
Study: NCT05836454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Group:
Description: Progressive muscle relaxation is a relaxation technique that involves regular and sequential contraction and relaxation of muscles until the whole body is relaxed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique Group
Description: It is a physiotherapy technique based on soft tissue mobilization. All enveloping fascia sale prices are positive for mobility, a user used for adhesions and pain.
Study: NCT05319236

Intervention type: DEVICE
Group type: OTHER
Intervention: Gabi System
Description: See arm description
Study: NCT06548659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: screen-based simulation
Description: Randomization took place among 198 people. The intervention group was given training on pediatric medication administration through screen-based simulation.
Study: NCT04438447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral feeding
Description: A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral feeding
Description: A 3-bag compartment peripheral parenteral solution (mOsm \< 800) containing carbohydrate, lipids and proteins will be infused to deliver 20/25 total Kcal/kg for a total of 5 days after the operation
Study: NCT06549010

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Perimetric test
Description: This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Perimetric test
Description: This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.
Study: NCT05594745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast Ophthalmic
Description: eyedrop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Free
Description: eyedrop

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow
Description: thermal pulsation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow
Description: thermal pulsation
Study: NCT06147726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity position matching exercises in virtual reality
Description: In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
Study: NCT06384911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives Program
Description: Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives Program
Description: Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives Program
Description: Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives Program
Description: Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.
Study: NCT04739696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPRR
Description: Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pep-Pal
Description: Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
Study: NCT06091488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopure
Description: Reconstruction of the anterior cruciate ligament of the knee in the patient.
Study: NCT06774937

Intervention type: DIAGNOSTIC_TEST
Intervention: All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his
Description: Thorough clinical examination:~1. General examination including general look, vital signs and anthropometric measurements.~2. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible).

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG ,rNST,Ach R antibodies & thyroid function
Description: C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible).